Soligenix, Inc. is a late-stage biopharmaceutical company focused

on developing and commercializing products to treat rare disease where there is

an unmet medical need.

They have two areas of focus: a specialized

biotherapeutics segment dedicated to the development of products for orphan

diseases and areas of unmet medical need such as cutaneous T-cell lymphoma,

oral mucositis, pediatric Crohn’s disease, and psoriasis. Also, a

public health solutions segment to develop vaccines and therapeutics

for military and civilian applications in the areas of ricin exposure, emerging

and antibiotic resistant infectious disease, and viral disease including Ebola,

Marburg and COVID-19.